Imcyse develops disease-specific immunotherapies using its proprietary Imotope™ platform, which employs synthetic peptides derived from naturally occurring proteins to recalibrate the immune system. The company targets severe autoimmune diseases, including Type 1 Diabetes and Multiple Sclerosis, by addressing the abnormal immune responses that contribute to these chronic conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for severe autoimmune diseases often manage symptoms and can have significant side effects, but do not provide a cure. These diseases, such as Type 1 Diabetes and Multiple Sclerosis, are characterized by abnormal immune responses where the body attacks its own tissues. There is a need for therapies that can specifically address the underlying immune dysfunction without broadly suppressing the immune system.
Solution
Imcyse is developing a new class of immunotherapies using its Imotope™ platform to target and recalibrate the immune system in patients with severe autoimmune diseases. The Imotope™ platform utilizes synthetic peptides, derived from naturally occurring proteins, to induce a specific and targeted immune response. This approach aims to halt the progression of autoimmune diseases by stopping the body's immune system from attacking healthy cells, potentially preserving organ function and minimizing the need for lifelong symptom management. Imcyse's pipeline includes clinical-stage programs in Type 1 Diabetes and Multiple Sclerosis, as well as preclinical programs in Neuromyelitis Optica, Rheumatoid Arthritis, and Celiac Disease.
Target Audience
The primary target audience includes individuals suffering from severe autoimmune diseases such as Type 1 Diabetes, Multiple Sclerosis, Neuromyelitis Optica, Rheumatoid Arthritis, and Celiac Disease, as well as the healthcare professionals who treat them.
Features
- Imotope™ Technology: Utilizes synthetic peptides based on naturally occurring proteins to modulate the immune system.
- Disease-Specific Immunotherapy: Targets the specific immune responses that contribute to autoimmune diseases.
- Clinical-Stage Programs: Investigating treatments for Type 1 Diabetes (IMCY-0098) and Multiple Sclerosis (IMCY-0141) in clinical trials.
- Preclinical Programs: Developing therapies for Neuromyelitis Optica (IMCY-0685), Rheumatoid Arthritis (in partnership with Pfizer), and Celiac Disease.
- Potential for Disease Modification: Aims to halt disease progression and preserve organ function.
- Targeted Immune Response: Designed to break abnormal immune responses and recalibrate the immune system.